Literature DB >> 21102196

Infectious keratitis treated with corneal crosslinking.

Karim Makdoumi1, Jes Mortensen, Sven Crafoord.   

Abstract

PURPOSE: To describe 7 eyes with severe infectious keratitis treated using collagen crosslinking (CXL) with riboflavin.
MATERIALS AND METHODS: Seven eyes of 6 patients with severe infectious keratitis were treated with corneal crosslinking. Three patients were contact lens users. Symptom duration before CXL ranged between 0 and 7 days. Corneal melting was present in all cases. Photodocumentation of the keratitis was carried out and repeated at follow-up. All but 1 patient received topical antibiotic treatment in addition to the CXL treatment. CXL was conducted according to the standardized protocol for keratoconus.
RESULTS: In all but 1 eye, patients experienced improvement in symptoms within 24 hours. Two patients reported no symptoms whatsoever at this time. Corneal melting was arrested and complete epithelialization was achieved in all cases. In the 2 eyes with hypopyon, this regressed completely within 2 days after the CXL. Follow-up ranged between 1 and 6 months. DISCUSSION: Our experience based on the above and other cases suggest that CXL could be an effective tool in battling difficult cases of infectious keratitis. This treatment could present many advantages but will need further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102196     DOI: 10.1097/ICO.0b013e3181d2de91

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  47 in total

1.  Cross-linking with ultraviolet-a and riboflavin reduces corneal permeability.

Authors:  Jay M Stewart; On-Tat Lee; Fergus F Wong; David S Schultz; Ricardo Lamy
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-29       Impact factor: 4.799

2.  Cross-Linking-Assisted Infection Reduction: A Randomized Clinical Trial Evaluating the Effect of Adjuvant Cross-Linking on Outcomes in Fungal Keratitis.

Authors:  N Venkatesh Prajna; Naveen Radhakrishnan; Prajna Lalitha; Ariana Austin; Kathryn J Ray; Jeremy D Keenan; Travis C Porco; Thomas M Lietman; Jennifer Rose-Nussbaumer
Journal:  Ophthalmology       Date:  2019-09-04       Impact factor: 12.079

3.  Spatially heterogeneous corneal mechanical responses before and after riboflavin-ultraviolet-A crosslinking.

Authors:  Joel R Palko; Junhua Tang; Benjamin Cruz Perez; Xueliang Pan; Jun Liu
Journal:  J Cataract Refract Surg       Date:  2014-04-18       Impact factor: 3.351

4.  Cosmetic preservatives as therapeutic corneal and scleral tissue cross-linking agents.

Authors:  Natasha Babar; MiJung Kim; Kerry Cao; Yukari Shimizu; Su-Young Kim; Anna Takaoka; Stephen L Trokel; David C Paik
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-29       Impact factor: 4.799

Review 5.  Corneal collagen cross-linking: a review.

Authors:  David P S O'Brart
Journal:  J Optom       Date:  2014-03-20

Review 6.  Update on the Management of Infectious Keratitis.

Authors:  Ariana Austin; Tom Lietman; Jennifer Rose-Nussbaumer
Journal:  Ophthalmology       Date:  2017-09-21       Impact factor: 12.079

7.  Corneal Cross-Linking Has No Effect on Matrix Metalloproteinase 9 and 13 Levels During Fungal Keratitis on the Early Stage.

Authors:  Ayse Kalkanci; Kamil Bilgihan; Huseyin Baran Ozdemir; Atiye Seda Yar Saglam; Funda Karakurt; Merve Erdogan
Journal:  Mycopathologia       Date:  2017-10-17       Impact factor: 2.574

8.  Collagen cross-linking for resistant corneal ulcer.

Authors:  Rana Sorkhabi; Mohamadreza Sedgipoor; Ali Mahdavifard
Journal:  Int Ophthalmol       Date:  2012-09-27       Impact factor: 2.031

9.  Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba castellanii.

Authors:  Karim Makdoumi; Anders Bäckman; Jes Mortensen; Anders Magnuson; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-19       Impact factor: 3.117

10.  Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.

Authors:  G Pron; L Ieraci; K Kaulback
Journal:  Ont Health Technol Assess Ser       Date:  2011-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.